Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMD Serono
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligible male and female subjects, aged 18 years or older
Must have at least moderately active SLE, as defined as SLE Disease Activity Index-2000 (SLEDAI-2K) score greater than or equal to \[\>=\] 6 at screening visit
At least 4 of the 11 American college of rheumatology (ACR) classification criteria for SLE (diagnosed \>= 6 months prior to the screening visit)
Be seropositive for anti-nuclear antibodies (ANA) and/or anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies
You may not be if
Subjects have demyelinating disorder
Severe central nervous system SLE
Use of cyclophosphamide within 3 months of the screening visit
Urine protein:creatinine ratio (UPCr) \>= 2 milligram per milligram (mg/mg) per day
Clareo Health | Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
